Arbor Biotechnologies, a next-generation gene editing company based in Cambridge, MA, is advancing a pipeline of novel gene editing therapeutics to address a wide range of genetic conditions - from the ultra-rare to the most common genetic diseases. The company's unique suite of optimized gene editors, which is capable of approaches ranging from gene knockout, excisions, reverse transcriptase editing, and large gene insertion, goes beyond the limitations of early editing technologies to unlock access to new gene targets and has fueled a robust pipeline of first-in-class assets focused on diseases of high unmet need. With Arbor's lead program, ABO-101 for the treatment of primary hyperoxaluria type 1, in clinical development, the company continues to focus their research and development efforts on genomic diseases of the liver and CNS for which there are no existing functional cures.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
03/31/25	$73,900,000	Series C	abrdn Ally Bridge Group ARCH Venture Partners ArrowMark Partners Deep Track Capital Kerna Ventures Partners Investment Co. Piper Heartland Healthcare Capital QIA Revelation Partners Surveyor Capital T. Rowe Price Associates TCGX Temasek Vertex Pharmaceuticals	undisclosed